Insulin Resistance Fieldguide · Answer guide
Fasting insulin vs A1C: which test tells you what?
A1C estimates average blood glucose over roughly three months; fasting insulin measures insulin in a fasting blood sample. They answer different questions. Prediabetes is identified using established glucose-test criteria, not a universal fasting-insulin cutoff advertised online.
Evidence behind this answer
Sources checked November 1, 2026: [1] NIDDK: diabetes tests and diagnosis[2] NIDDK: recommended prediabetes tests and ranges[3] NIDDK: insulin resistance and prediabetes
| Test | Main information | Important limit |
|---|---|---|
| A1C | Longer-term average glucose estimate | Not a direct insulin-sensitivity test |
| Fasting plasma glucose | Glucose after fasting | One type of glucose assessment |
| Fasting insulin | Insulin concentration after fasting | No universal consumer diagnostic cutoff for insulin resistance |
Evidence in context
Glucose criteria answer a different question from insulin sensitivity.
What the source reports
NIDDK lists separate glucose-based thresholds for prediabetes and diabetes. Different tests can identify different people. A diabetes diagnosis usually needs confirmation with a second test; pregnancy has different testing considerations.
How far the conclusion goes
These tests do not provide interchangeable numerical measurements of insulin resistance. An insulin result should not be interpreted using a glucose cutoff.
Why might a clinician choose another test when A1C looks normal?
The tests measure different aspects of glucose regulation, and clinical history matters. A normal result on one test does not make all other assessments redundant.
Source: NIDDK: diabetes tests and diagnosis ↗
Checked November 1, 2026. Our interpretation is educational; this is not an independent clinical review.
What A1C is used for
A1C reflects the proportion of hemoglobin with glucose attached and is used in diabetes and prediabetes assessment. It does not directly measure insulin concentration or sensitivity. Certain blood conditions, pregnancy and other circumstances can affect how it should be interpreted. A normal A1C should not be relabeled as proof that every aspect of metabolic health is normal; equally, an isolated insulin result should not override a clinical evaluation.
What fasting insulin adds—and what it does not
Insulin assays can be useful in selected evaluations and research. Results depend on the assay and context. Online “optimal” ranges and home HOMA-IR calculations are not interchangeable with universally standardized diagnostic thresholds. The meaningful question is whether the result changes a clinical decision. Ordering increasingly large panels without that purpose can create apparently precise labels without a clear next step.
The established prediabetes ranges
NIDDK lists A1C 5.7–6.4%, fasting plasma glucose 100–125 mg/dL, or two-hour glucose after an oral glucose tolerance test 140–199 mg/dL as prediabetes ranges. These are different tests and may identify different people. They are not direct insulin-resistance ranges. Diagnosis and the need for repeat or alternative testing belong in the clinical context, especially if results conflict or symptoms are present.
How to compare your own results
Keep the test name, date, units and fasting instructions alongside each result. Do not compare a laboratory glucose result with a casual home reading as though the methods were identical. Ask why a particular test was selected and when it should be repeated. A lower number on an unvalidated commercial score is less useful than an agreed plan addressing an established risk or diagnosis.
Related questions
Can A1C miss a glucose problem?
Different glucose tests do not always identify the same people. Your clinician may use another test where indicated; this does not mean everyone needs every available test.
Should everyone buy a fasting insulin test?
No universal recommendation follows from this comparison. A test should answer a relevant clinical question.
Sources
General information, not an individual diagnosis or treatment plan. Product-specific approval, risks and eligibility must be checked against the current label and clinical assessment. How we publish · Report a correction